Malignant tumors have become one of the public health problems that seriously threaten the health of the Chinese population. On the road to conquering malignant tumors, the most eye-catching in recent years is the latest CAR-T cell therapy. What malignant tumors can CAR-T cell therapy treat? What is the latest development of CAR-T cell therapy in China? Recently, in the East Lake High-tech Wuhan Optics Valley International Biomedical Enterprise Accelerator, a seminar on “Accelerating the Development of CAR-T Drugs” was held here.
A patient with acute lymphoblastic B-cell leukemia shares her experience. After being diagnosed with the disease in 2018, after 4 months of chemotherapy, Ms. Hu did not get the expected results.
With the attitude of giving it a try, Ms. Hu joined CAR-T cell therapy. in clinical trials. In January 2019, Ms. Hu re-infused autologous CAR-T cells transformed with genetic engineering technology.
Ms. Hu:
“In less than half a month, all my indicators Everything has returned to normal. So far, it has been 3 years and 2 months. At present, I am very good in all aspects. I don’t need to take medicine or injections. I don’t need anything. /span>
CAR-T cell therapy is obtained from human blood Extract T cells, transform them into CAR-T cells that can recognize and destroy tumors by applying genetic engineering technology, and then inject them into patients. So as to achieve the effect of destroying cancer cells.
Tongcun Zhang, Dean of School of Life Science and Health, Wuhan University of Science and Technology :
“CAR-T should be a great success in hematological tumors, especially acute B lymphocytic leukemia. Currently Domestic and international CAR-T products are also mainly concentrated in this area, CAR-T targeting CD19, but there are no new products for other hematological tumors, such as Hodgkin’s lymphoma. Our company targets CD30. The target, which is Hodgkin’s lymphoma, we are currently at the forefront of the world, and it is expected to become the world’s first marketed product.”
Among the CAR-T products registered for clinical trials in China, the proportion of hematological tumor treatment fields far exceeds that of solid tumors. There are still some difficulties that need to be overcome in the CAR-T treatment of some solid tumors. The CAR-T cell-loaded oncolytic virus treatment project of Professor Zhang’s team provides a new idea for CAR-T in the treatment of solid tumors.
Tongcun Zhang, Dean of School of Life Science and Health, Wuhan University of Science and Technology :
“Our company is currently making breakthroughs in the treatment of solid tumors. Our CAR-T targeting CD99 targets The first patent in the world, the first clinical application, has successfully treated two patients with (Ewing’s) sarcoma, both of which have achieved complete remission. We are currently accelerating the IND of CD99 I hope the country can approve the entry into clinical registration as soon as possible.”
